Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association Between Microscopic Hematuria and Proteinuria Remission in Adult Nephrotic Syndrome.

Kidney medicine·2026

Same author

Polyclonal immunoglobulin G deposits with distinctive appearance in the tubular basement membrane: a report of two cases.

BMC nephrology·2025

Same author

Association between Urinary Fractional Excretion of Potassium and Proteinuria Remission in Adult Nephrotic Syndrome.

Kidney360·2025

Same author

Proximal-tubule molecular relay from early Protein diaphanous homolog 1 to late Rho-associated protein kinase 1 regulates kidney function in obesity-induced kidney damage.

Kidney international·2022

Same author

Diagnosis of monoclonal immunotactoid glomerulopathy with positive λ chain by immunoelectron microscopy.

CEN case reports·2022

Same author

Home-Based Exercise Program Ameliorates Renal Function Decline in Patients With CKD Stage 4.

Kidney international reports·2022

Search research articles

Related Experiment Video

Updated: Jul 1, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

[Obesity in CKD].

Hirobumi Tokuyama¹, Shu Wakino, Hiroshi Ito

¹Department of Medicine, Keio University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|September 16, 2008

Summary

Obesity drives metabolic syndrome, leading to kidney disease through insulin resistance and inflammation. Early changes in the kidney resemble diabetic kidney disease, highlighting the link between obesity and chronic kidney disease (CKD).

Area of Science:

Nephrology
Metabolic Diseases
Obesity Research

Background:

Metabolic syndrome, marked by obesity, high blood pressure, and insulin resistance, is a significant risk factor for kidney disease.
Obesity is a primary driver of metabolic syndrome, initiating kidney changes similar to diabetic kidney disease early on.

Purpose of the Study:

To review the mechanisms by which obesity induces chronic kidney disease (CKD).
To explore the specific relationship between insulin resistance and CKD in the context of obesity.

Main Methods:

Review of existing studies on histologic and functional kidney changes in early-stage obesity.
Analysis of the role of Rho-kinase and perinephric adipose tissue in obesity-related renal inflammation.

Related Experiment Videos

Last Updated: Jul 1, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Main Results:

High-fat diets in obesity models induce increased arterial pressure, hyperinsulinemia, and glomerular hyperfiltration.
Obesity-related renal injury involves Rho-kinase activation and inflammatory chemokines from perinephric fat.

Conclusions:

Obesity initiates kidney damage through metabolic dysregulation and inflammation, contributing to CKD.
Insulin resistance is a key factor linking obesity to the progression of chronic kidney disease.